Compare conditions

Put any two — or three — conditions side by side, adult or pediatric, to spot the look-alike differences fast, row by row.

Cirrhosis-Associated Coagulation Dysfunction

—

In one line

·Cirrhosis creates a rebalanced but fragile coagulation system where both clotting and bleeding risks coexist because the liver can no longer make normal amounts of pro-clotting and anti-clotting proteins.

—

Normal physiology

·The liver makes most of the proteins needed for blood clotting (procoagulants) and most of the proteins that stop clots from growing too large (anticoagulants). These proteins circulate in the blood in an inactive form until injury occurs. When a blood vessel is cut, clotting factors activate in a careful sequence to form a clot, while anticoagulant proteins prevent the clot from spreading beyond the injury site.

—

What goes wrong

·In cirrhosis, scar tissue replaces healthy liver cells, so the liver cannot make normal amounts of clotting proteins or anti-clotting proteins. Blood tests like the INR (international normalized ratio) go up because clotting factors drop, but this does not mean the patient will bleed. The balance between clotting and anti-clotting is reset at a lower level that works until infection, kidney failure, or other stress tips the balance.

—

Hallmark signs

—

Red flags · escalate now

·Vomiting blood (Hematemesis) (vomiting bright red blood) or black tarry stool (melena) (black tarry stools) indicating active gastrointestinal bleeding
·INR above 3.0 with any bleeding symptom suggesting severe impaired blood clotting (coagulopathy) requiring immediate factor replacement
·Platelet count below 20,000 with spontaneous bleeding into skin or mucous membranes
·Sudden severe abdominal pain with low blood pressure (hypotension) (systolic BP below 90) suggesting variceal rupture or intra-abdominal bleeding (hemorrhage)

—

Workup

—

Treatment

·Fresh frozen plasma (FFP) transfusion before invasive procedures
·Platelet transfusion when count below 50,000 before procedures or below 10,000 with active bleeding
·Non-selective beta-blockers (propranolol or carvedilol) for variceal bleeding prevention (prophylaxis)
·Endoscopic variceal ligation (banding) for high-risk varices or active bleeding
·Vitamin K supplementation 10 mg subcutaneous or oral for 3 days
·Transjugular intrahepatic portosystemic shunt (TIPS) for refractory variceal bleeding

—

NCLEX trap

·INR is unreliable for bleeding prediction in cirrhosis; preventive (prophylactic) plasma transfusion does not reduce procedural bleeding and may cause volume overload and transfusion reactions; only give for active bleeding
·Platelet count does not predict bleeding in cirrhosis; transfused platelets are quickly sequestered by the enlarged spleen and provide no lasting benefit; reserve transfusion for active bleeding with platelets below 10,000-20,000
·Cirrhotic patients usually have adequate vitamin K; the problem is damaged liver cells cannot use vitamin K to synthesize clotting factors; vitamin K trial is reasonable but rarely corrects INR significantly in cirrhosis
·Cirrhosis creates rebalanced hemostasis with equal risk of bleeding and clotting; portal vein clot formation (thrombosis) (clot in the main liver vein) occurs in up to 25% of cirrhotic patients; assess for both risks
·Anticoagulation decisions in cirrhosis are complex; the elevated baseline INR makes monitoring difficult, and bleeding risk is high; low-molecular-weight heparin or direct oral anticoagulants may be used cautiously with gastroenterology and hematology guidance
·Factor VIIa is expensive, carries clot formation (thrombosis) risk, and has not been proven to reduce bleeding in cirrhosis; it is reserved for life-threatening bleeding unresponsive to other measures and is not for routine prevention (prophylaxis)

—

Install Maldek by Hill as an app — studies work even offline